scholarly journals Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling

2021 ◽  
Author(s):  
Felix Huth ◽  
Hilmar Schiller ◽  
Yi Jin ◽  
Birk Poller ◽  
Carole Schuhler ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Clinical Data ◽  
Interaction Potential ◽  
Kinase Inhibitor ◽  
Pbpk Modeling ◽  
Bruton's Tyrosine Kinase ◽  
Cyp3a4 Inhibitors ◽  
Drug Drug Interaction

scholarly journals Long-term follow-up of patients with CLL treated with the selective Bruton’s tyrosine kinase inhibitor ONO/GS-4059

Blood ◽  
2017 ◽  
Vol 129 (20) ◽  
pp. 2808-2810 ◽  
Author(s):  
Harriet S. Walter ◽  
Sandrine Jayne ◽  
Simon A. Rule ◽  
Guillaume Cartron ◽  
Franck Morschhauser ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Kinase Inhibitor ◽  
Bruton’S Tyrosine Kinase ◽  
Bruton's Tyrosine Kinase ◽  
Long Term Follow Up
Sign in / Sign up

Export Citation Format

Share Document